Results 81 to 90 of about 30,645 (194)

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase [PDF]

open access: yes, 2003
Background and aims: Interferon (IFN) induced hepatitis B e antigen (HBeAg) seroconversion is durable in 80-90% of chronic hepatitis B patients.
Hansen, B.E. (Bettina)   +32 more
core   +2 more sources

Artificial neural network accurately predicts hepatitis B surface antigen seroclearance.

open access: yesPLoS ONE, 2014
Background & aimsHepatitis B surface antigen (HBsAg) seroclearance and seroconversion are regarded as favorable outcomes of chronic hepatitis B (CHB).
Ming-Hua Zheng   +10 more
doaj   +1 more source

HBV RNA Predicts the Risk of Off‐Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta‐Analysis

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Since there are currently few antiviral drugs that can effectively reduce hepatitis B surface antigen levels, the recurrence rate remains high in patients with chronic hepatitis B (CHB) after discontinuing nucleoside analogues (NAs) treatment.
Dong‐Hui Wang   +8 more
wiley   +1 more source

Prevalence and Risk Factors of Elevated Alanine Aminotransferase (ALT) in 2382 Treatment‐naïve HBV/HDV Co‐Infected Patients

open access: yesLiver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background Chronic hepatitis D (CHD) causes severe chronic hepatitis. Knowledge is limited about factors correlating with ALT in treatment‐naïve patients with CHD. This study analysed the pattern and determinants of ALT elevation in a large cohort of patients with CHD, including young adults, compared to propensity score‐matched (PSM) patients
Habiba Kamal   +13 more
wiley   +1 more source

HBV RNA AS A PREDICTOR OF HBEAG SEROCONVERSION IN PATIENTS WITH HEPATITIS B

open access: yesWorld Journal of Clinical Sciences
Objective: To study the predictive value of serum hepatitis B virus pregenomic RNA (HBV pgRNA) in the seroconversion of HBeAg-positive chronic hepatitis B (CHB) patients. Methods: 135 patients with HBeAg positive CHB patients were admitted to our hospital from June 2021 to June 2022 were selected to detect the serum HBV pgRNA and HBV DNA levels with ...
Jun Tian   +3 more
openaire   +1 more source

Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH)

open access: yesLiver International, Volume 46, Issue 4, April 2026.
ABSTRACT The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral Hepatitis (ESGVH) convened to examine the role of vaccination as the cornerstone of hepatitis prevention ...
Oana Săndulescu   +5 more
wiley   +1 more source

Impact of Metabolic Associated Steatotic Liver Disease on Antiviral Therapy Outcomes on Chronic Hepatitis B Patients Receiving Antiviral Therapy

open access: yesJournal of Medical Virology, Volume 98, Issue 3, March 2026.
ABSTRACT Background and Aim Chronic hepatitis B (CHB) affects over 250 million people globally and is a major contributor to liver complications, including cirrhosis and hepatocellular carcinoma (HCC). Though antiviral therapies suppress HBV, the rising prevalence of metabolic‐associated steatotic liver disease (MASLD) poses new challenges.
Sheng‐Jie Shiue   +12 more
wiley   +1 more source

Immunomodulatory Function of HBeAg Related to Short-Sighted Evolution, Transmissibility, and Clinical Manifestation of Hepatitis B Virus

open access: yesFrontiers in Microbiology, 2018
Hepatitis B virus (HBV) infection, a global public health problem can be asymptomatic, acute or chronic and can lead to serious consequences of infection, including cirrhosis, and hepatocellular carcinoma.
Anna Kramvis   +3 more
doaj   +1 more source

The power of nodal width>8mm at acute flare and nodal change>3mm between acute flare and recovery stage to predict HBeAg seroconversion in study and validation group.

open access: yes, 2015
Abbreviations: e SC+: positive HBeAg seroconversion, eSC-: negative HBeAg seroconversion, WT: nodal width, dWT: The nodal size change for nodal width between acute flare stage and recovery stage.*p-value is from Pearson’s chi-square test.The power of ...
Kun-Ming Chung (523221)   +9 more
core   +1 more source

Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C

open access: yes, 2004
The aims of this study were to compare chronic hepatitis B (CHB) patients with genotypes B and C for the probability of HBeAg seroconversion, hepatitis activity, and viral replication before and after HBeAg seroconversion and to compare the prevalence of
Kato, T   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy